MicroRNAs in gastrointestinal cancer: a novel biomarker and its clinical application

Abstract

Gastrointestinal (GI) cancers remain one of the most common malignancies and are the major cause of cancer deaths worldwide. Significant advancements have improved our understanding of the pathogenesis and pathology of GI cancers, but high mortality rates, an unfavorable prognosis, and lack of clinical predictive biomarkers provide an impetus to investigate novel diagnostic/prognostic markers and therapeutic targets for GI cancers. MicroRNAs (miRNAs) are short (19-24 nucleotides), non-coding RNA molecules that regulate gene expression at the post-transcriptional level, thus playing an important role in modulating various biological processes. This includes developmental processes, proliferation, apoptosis, metabolism and differentiation, all involved in initiation and progression of various human cancers. Aberrant miRNA expression profiles have been observed in various cancer types at different stages, suggesting their potential as diagnostic and prognostic biomarkers. Due to their tumor- and tissue-specific expression profiles, stability, and the availability of robust clinical assays for their detection in serum as well as in formalin-fixed tissue samples, miRNAs have emerged as attractive candidates for diagnostic and prognostic applications. This review summarizes recent research supporting the utility of miRNAs as novel diagnostic/prognostic tools and therapeutic targets, thus potentially illuminating future treatment strategies for GI cancers.

Keywords

Biomarker / gastrointestinal cancer / microRNA / therapeutic target

References

[1] Marusawa H.Inflammation and gastrointestinal cancer: an overview..Cancer Lett2014;345:153-6

[2] Gartel AL.miRNAs: Little known mediators of oncogenesis..Semin Cancer Biol2008;18:103-10

[3] Friedman RC,Burge CB.Most mammalian mRNAs are conserved targets of microRNAs..Genome Res2009;19:92-105 PMCID:PMC2612969

[4] Ambros V.The functions of animal microRNAs..Nature2004;431:350-5

[5] Calin GA.MicroRNA signatures in human cancers..Nat Rev Cancer2006;6:857-66

[6] Johnson CD,Stefani G,Kelnar K,Wilson M,Shelton J,Chin L,Slack FJ.The let-7 microRNA represses cell proliferation pathways in human cells..Cancer Res2007;67:7713-22

[7] Kent OA.A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes..Oncogene2006;25:6188-96

[8] Fassan M,Rugge M.miRNAs in precancerous lesions of the gastrointestinal tract..World J Gastroenterol2011;17:5231-9 PMCID:PMC3247686

[9] Song B.Impact of miRNAs in gastrointestinal cancer diagnosis and prognosis..Expert Rev Mol Med2010;12:e33

[10] Boni V,Zarate R,Maiello E.MicroRNAs as a new potential therapeutic opportunity in gastrointestinal cancer..Oncology2009;77 Suppl 1:75-89

[11] Vicentini C,D'Angelo E,Silvestris N,Scarpa A.Clinical application of microRNA testing in neuroendocrine tumors of the gastrointestinal tract..Molecules2014;19:2458-68

[12] Macha MA,Krishn SR,Rachagani S,Batra SK.MicroRNAs (miRNAs) as biomarker(s) for prognosis and diagnosis of gastrointestinal (GI) cancers..Curr Pharm Des2014;20:5287-97 PMCID:PMC4113605

[13] Parkin DM,Ferlay J.Global cancer statistics, 2002..CA Cancer J Clin2005;55:74-108

[14] Enzinger PC.Esophageal cancer..N Engl J Med2003;349:2241-52

[15] He B,Wang B,Chen C.MicroRNAs in esophageal cancer (review)..Mol Med Rep2012;6:459-65

[16] Guo Y,Zhang L,Shi S,Li B,Ma X,Shao K,Qiu B,Cheng J.Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma..Cancer Res2008;68:26-33

[17] Feber A,Luketich JD,Landreneau RJ,Swanson SJ,Litle VR.MicroRNA expression profiles of esophageal cancer..J Thorac Cardiovasc Surg2008;135:255-60

[18] Mathe EA,Bowman ED,Budhu A,Braun R,Kumamoto K,Altorki NK,Liu CG,Yanaihara N,Dannenberg AJ,Croce CM.MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival..Clin Cancer Res2009;15:6192-200 PMCID:PMC2933109

[19] Kan T.MicroRNAs in Barrett's esophagus and esophageal adenocarcinoma..Curr Opin Pharmacol2009;9:727-32 PMCID:PMC2794797

[20] Maru DM,Hannah C,Li YX,Romans AM,Luthra MG,Swisher SG,Rashid A.MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus..Am J Pathol2009;174:1940-8

[21] Ogawa R,Kuwabara Y,Mitsui A,Harata K,Fujii Y.Expression profiling of micro-RNAs in human esophageal squamous cell carcinoma using RT-PCR..Med Mol Morphol2009;42:102-9

[22] Zhang T,Wang Q,Cui Y,Lu SH.MicroRNA-1322 regulates ECRG2 allele specifically and acts as a potential biomarker in patients with esophageal squamous cell carcinoma..Mol Carcinog2013;52:581-90

[23] Lin RJ,Liao LD,Xie ZF,Wang WS,Wu BL,Xu LY.MiR-142-3p as a potential prognostic biomarker for esophageal squamous cell carcinoma..J Surg Oncol2012;105:175-82

[24] Leidner RS,Leahy P,Bednarchik B,Canto M,Maitra A,Markowitz SD,Adams MD,Guda K.The microRNAs, MiR-31 -and MiR-375, as candidate markers in Barrett's esophageal carcinogenesis..Genes Chromosomes Cancer2012;51:473-9 PMCID:PMC3547654

[25] Hu Y,Hoque A,Ye F,Swisher SG,Ajani JA.Prognostic significance of differentially expressed miRNAs in esophageal cancer..Int J Cancer2011;128:132-43

[26] Komatsu S,Takeshita H,Morimura R,Kosuga T,Konishi H,Fujiwara H,Otsuji E.Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma..Br J Cancer2011;105:104-11 PMCID:PMC3137413

[27] Zhang C,Chen X,Li K,Dai J,Zhou X,Zhang Y,Qiu H,Liang Z,Yang C,Zhang CY.Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma..Clin Chem2010;56:1871-9

[28] Zhang T,Zhao D,Cao B,Lu SH.The oncogenetic role of microRNA-31 as a potential biomarker in oesophageal squamous cell carcinoma..Clin Sci (Lond).2011;121:437-47

[29] Hummel R,Watson DI,Van der Hoek M,Hussey DJ.Chemotherapy-induced modification of microRNA expression in esophageal cancer..Oncol Rep2011;26:1011-7

[30] Imanaka Y,Sato F,Shimizu K.MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma..J Hum Genet2011;56:270-6

[31] Zhang H,Han Y,Gong T,Zheng X.Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma..Dig Dis Sci2010;55:2545-51

[32] Hong L,Zhang H,Gong T,Wu K,Fan D.The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma..Ann Surg2010;251:1056-63

[33] Hamano R,Yamasaki M,Hara J,Nakajima K,Fujiwara Y,Doki Y.Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway..Clin Cancer Res2011;17:3029-38

[34] Hummel R,Smith C,Michael MZ,Hussey DJ.Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells..J Gastrointest Surg2011;15:429-38

[35] Wu Y,Ding X,Ren P,Zhou J.A -miR-200b/200c/429-binding site polymorphism in the 3' untranslated region of the AP-2alpha gene is associated with cisplatin resistance..PLoS One2011;6:e29043

[36] Ferlay J,Bray F,Mathers C.Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008..Int J Cancer2010;127:2893-917

[37] Coburn NG.Lymph nodes and gastric cancer..J Surg Oncol2009;99:199-206

[38] Wu WK,Cho CH,Wu K,Sung JJ.MicroRNA dysregulation in gastric cancer: a new player enters the game..Oncogene2010;29:5761-71

[39] Song S.The role of microRNAs in cancers of the upper gastrointestinal tract..Nat Rev Gastroenterol Hepatol2013;10:109-18 PMCID:PMC3855852

[40] Matuszcak C,Hummel R.MicroRNAs: promising chemoresistance biomarkers in gastric cancer with diagnostic and therapeutic potential..World J Gastroenterol2014;20:13658-66 PMCID:PMC4194550

[41] Song MY,Su HJ,Ma JL,Yuasa Y,Kim YS.Identification of serum microRNAs as novel non-invasive biomarkers for early detection of gastric cancer..PLoS One2012;7:e33608

[42] Konishi H,Komatsu S,Tsujiura M,Morimura R,Arita T,Hirashima S,Okamoto K.Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre- and post-operative plasma..Br J Cancer2012;106:740-7 PMCID:PMC3322946

[43] Liu H,Liu B,Meng X,Ma Y.Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer..Cancer Lett2012;316:196-203

[44] Liu R,Hu Z,Wang C,Huang D,Zhang H,Deng T,Yin J,Zen K,Zhang CY.A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis..Eur J Cancer2011;47:784-91

[45] Tsujiura M,Komatsu S,Takeshita H,Konishi H,Deguchi K,Okamoto K.Circulating microRNAs in plasma of patients with gastric cancers..Br J Cancer2010;102:1174-9 PMCID:PMC2853097

[46] Zhou H,Lou YR,Zhong FD,Cheng J.Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker..J Mol Med (Berl).2010;88:709-17

[47] Li X,Zhang Y,Wu K.Survival prediction of gastric cancer by a seven-microRNA signature..Gut2010;59:579-85

[48] Katada T,Kuwabara Y,Mitui A,Ogawa R,Fujii Y.microRNA expression profile in undifferentiated gastric cancer..Int J Oncol2009;34:537-42

[49] Chen L,Yuan W.Prognostic value of -miR-93 overexpression in resectable gastric adenocarcinomas..Acta Gastroenterol Belg2012;75:22-7

[50] Bandres E,Arias F,Fortes P,Zarate R,Ramirez N,Jimenez P,Garcia-Foncillas J.microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells..Clin Cancer Res2009;15:2281-90

[51] Tie J,Zhao L,Liu J,Guo X,Gang Y,Li Q,Zhao Q,Fan D.MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor..PLoS Genet2010;6:e1000879

[52] Ueda T,Okumura H,Taccioli C,Alder H,Oue N,Yoshida K,Nomura S,Kaminishi M,Croce CM.Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis..Lancet Oncol2010;11:136-46

[53] Wang M,Wang S,Zhu W,Zhao C,Xu W.Circulating miR-17-5p and miR-20a: molecular markers for gastric cancer..Mol Med Rep2012;5:1514-20

[54] Yang Q,Cao H,Yang C,Jiang Y.Low-level expression of let-7a in gastric cancer and its involvement in tumorigenesis by targeting RAB40C..Carcinogenesis2011;32:713-22

[55] Kim CH,Rettig RL,Lee ET,Choi IJ,Green JE.miRNA signature associated with outcome of gastric cancer patients following chemotherapy..BMC Med Genomics2011;4:79 PMCID:PMC3287139

[56] Chen L,Kong WQ,Liu M,Tang H.MicroRNA-181b targets cAMP responsive element binding protein 1 in gastric adenocarcinomas..IUBMB Life2012;64:628-35

[57] Hashiguchi Y,Mimori K,Tanaka F,Ishii H,Hase K,Mori M.Down-regulation of miR-125a-3p in human gastric cancer and its clinicopathological significance..Int J Oncol2012;40:1477-82

[58] Zheng B,Huang S,Liu L,Tian Q,Wang C,Zhou Y,Du C,He X.MicroRNA-409 suppresses tumour cell invasion and metastasis by directly targeting radixin in gastric cancers..Oncogene2012;31:4509-16

[59] Yang SM,Li XF,He Y.miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN..Toxicology2013;306:162-8

[60] Deng H,Song H,Sun W,Yu X,Cui L.MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetical regulation in gastric cancer..Gene2013;518:351-9

[61] Shang Y,Liu Z,Ren G,Zhou L,Li M,An Y,Nie Y.miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1..Oncogene2014;33:3267-76

[62] Hu J,Cao Y,Chen Q.miR-449a Regulates proliferation and chemosensitivity to cisplatin by targeting cyclin D1 and BCL2 in SGC7901 cells..Dig Dis Sci2014;59:336-45

[63] Zhao X,Hu J.Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells..J Exp Clin Cancer Res2011;30:55 PMCID:PMC3120716

[64] Lieberman D.Progress and challenges in colorectal cancer screening and surveillance..Gastroenterology2010;138:2115-26

[65] Ng EK,Jin H,Shin VY,Poon TC,Sung JJ.Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening..Gut2009;58:1375-81

[66] Huang Z,Ni S,Sheng W.Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer..Int J Cancer2010;127:118-26

[67] Cheng H,Cogdell DE,Schetter AJ,Harris CC,Hamilton SR.Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis..PLoS One2011;6:e17745

[68] Link A,Shen Y,Lozano JJ,Goel A.Fecal MicroRNAs as novel biomarkers for colon cancer screening..Cancer Epidemiol Biomarkers Prev2010;19:1766-74 PMCID:PMC2901410

[69] Koga Y,Takahashi A,Moriya Y,Fujita S,Baba H.MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening..Cancer Prev Res (Phila)2010;3:1435-42

[70] Kalimutho M,Del Vecchio Blanco G,Sileri P,Formosa A,Marrelli D,Federici G.Epigenetically silenced miR-34b/c as a novel faecal-based screening marker for colorectal cancer..Br J Cancer2011;104:1770-8 PMCID:PMC3111174

[71] Schetter AJ,Sohn JJ,Bowman ED,Yuen ST,Kwong DL,Liu CG,Croce CM.MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma..JAMA2008;299:425-36 PMCID:PMC2614237

[72] Shibuya H,Shimada R,Watanabe T.Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer..Oncology2010;79:313-20

[73] Kulda V,Topolcan O,Treska V,Rupert K,Babuska V,Cerny R.Relevance of miR-21 and miR-143 expression in tissue samples of colorectal carcinoma and its liver metastases..Cancer Genet Cytogenet2010;200:154-60

[74] Nielsen BS,Fog JU,Christensen IJ,Brunner N,Moller S.High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients..Clin Exp Metastasis2011;28:27-38 PMCID:PMC2998639

[75] Diaz R,Garcia JM,Garcia V,Rodriguez R,Garcia F,Dominguez G.Deregulated expression of miR-106a predicts survival in human colon cancer patients..Genes Chromosomes Cancer2008;47:794-802

[76] Schepeler T,Ostenfeld MS,Silahtaroglu AN,Wiuf C,Kruhoffer M,Kauppinen S,Andersen CL.Diagnostic and prognostic microRNAs in stage II colon cancer..Cancer Res2008;68:6416-24

[77] Nishida N,Mimori K,Tanaka F,Ishii H,Kuwano H.MicroRNA miR-125b is a prognostic marker in human colorectal cancer..Int J Oncol2011;38:1437-43

[78] Drebber U,Wedemeyer I,Bollschweiler E,Monig SP,Dienes HP.Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy..Int J Oncol2011;39:409-15

[79] Akcakaya P,Kolosenko I,Ozata DM,Lindforss U,Lui WO.miR-185 and miR-133b deregulation is associated with overall survival and metastasis in colorectal cancer..Int J Oncol2011;39:311-8

[80] Karaayvaz M,Song B,Georgakopoulos P,Burke S,Ju J.Prognostic significance of miR-215 in colon cancer..Clin Colorectal Cancer2011;10:340-7 PMCID:PMC3390153

[81] Yu G,Tian ML,Wang X,Zhu J,Wan YL.Prognostic values of the miR-17-92 cluster and its paralogs in colon cancer..J Surg Oncol2012;106:232-7

[82] Faber C,Hlubek F.Overexpression of Dicer predicts poor survival in colorectal cancer..Eur J Cancer2011;47:1414-9

[83] Valeri N,Braconi C,Lovat F,Sumani KM,Amadori D,Nuovo GJ,Croce CM.MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2)..Proc Natl Acad Sci U S A2010;107:21098-103 PMCID:PMC3000294

[84] Rossi L,Faraoni I.Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluorouracil in vitro..Pharmacol Res2007;56:248-53

[85] Song B,Xi Y,Bruheim S,Gavin E,Formentini A,Fodstad O.Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells..Oncogene2009;28:4065-74 PMCID:PMC2783211

[86] Song B,Titmus MA,Formentini A,Ju J.Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells..Mol Cancer2010;9:96 PMCID:PMC2881118

[87] Mencia N,Noe V.Underexpression of miR-224 in methotrexate resistant human colon cancer cells..Biochem Pharmacol2011;82:1572-82

[88] Chai H,Tian R,Tang H.miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines..Acta Biochim Biophys Sin (Shanghai).2011;43:217-25

[89] Ibrahim AF,Thomas M,Hartmann RK.MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma..Cancer Res2011;71:5214-24

[90] Yang JD.Epidemiology and management of hepatocellular carcinoma..Infect Dis Clin North Am2010;24:899-919, viii

[91] Bruix J.Management of hepatocellular carcinoma..Hepatology2005;42:1208-36

[92] Siegel R,Jemal A.Cancer statistics, 2012..CA Cancer J Clin2012;62:10-29

[93] Huang XB,Zheng L,Han KQ,Liang P.Bioinformatics analysis reveals potential candidate drugs for HCC..Pathol Oncol Res2013;19:251-8

[94] El-Serag HB.Hepatocellular carcinoma and hepatitis C in the United States..Hepatology2002;36:S74-83

[95] Lin CL.Hepatitis B viral factors and clinical outcomes of chronic hepatitis B..J Biomed Sci2008;15:137-45

[96] Zhu Z,Wang G.Role of MicroRNAs in Hepatocellular Carcinoma..Hepat Mon2014;14:e18672

[97] Otsuka M,Yoshikawa T,Takata A,Koike K.The role of microRNAs in hepatocarcinogenesis: current knowledge and future prospects..J Gastroenterol2014;49:173-84

[98] Hung CH,Chen CH.MicroRNAs in hepatocellular carcinoma: carcinogenesis, progression, and therapeutic target..Biomed Res Int2014;2014:486407 PMCID:PMC3996893

[99] Petrelli A,Cora D,Menegon S,Migliore C,Ledda-Columbano GM,Columbano A.MicroRNA/gene profiling unveils early molecular changes and nuclear factor erythroid related factor 2 (NRF2) activation in a rat model recapitulating human hepatocellular carcinoma (HCC)..Hepatology2014;59:228-41

[100] Xu J,Che X,Yu D,Huang L,Tan W,Lin D.Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis..Mol Carcinog2011;50:136-42

[101] Li J,Yu W,Luo J.Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance..Biochem Biophys Res Commun2011;406:70-3

[102] Tomimaru Y,Nagano H,Kobayashi S,Tanemura M,Takemasa I,Kanto T,Mori M.Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma..J Hepatol2012;56:167-75

[103] Li LM,Zhou ZX,Liu FY,Shen HB,Zen K.Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma..Cancer Res2010;70:9798-807

[104] Liu AM,Wang W,Lee NP,Poon RT,Luk JM.Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study..BMJ Open2012;2:e000825

[105] Hou W.Non-coding RNAs in hepatitis C-induced hepatocellular carcinoma: dysregulation and implications for early detection, diagnosis and therapy..World J Gastroenterol2013;19:7836-45 PMCID:PMC3848131

[106] Qu KZ,Li H,Albitar M.Circulating microRNAs as biomarkers for hepatocellular carcinoma..J Clin Gastroenterol2011;45:355-60

[107] Hu QY,Su J.MicroRNAs as biomarkers for hepatocellular carcinoma: a diagnostic meta-analysis..Clin Lab2013;59:1113-20

[108] Wang XW,Orum H.MicroRNAs in liver disease..Gastroenterology2012;142:1431-43

[109] Janssen HL,Lawitz EJ,Rodriguez-Torres M,van der Meer AJ,Chen A,Persson R,Kauppinen S,Hodges MR.Treatment of HCV infection by targeting microRNA..N Engl J Med2013;368:1685-94

[110] Jopling CL,Lancaster AM,Sarnow P.Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA..Science2005;309:1577-81

[111] Fukuhara T.Role of miR-122 and lipid metabolism in HCV infection..J Gastroenterol2013;48:169-76 PMCID:PMC3698423

[112] Bouchie A.First microRNA mimic enters clinic..Nat Biotechnol2013;31:577

[113] de Groen PC,LaRusso NF,Nagorney DM.Biliary tract cancers..N Engl J Med1999;341:1368-78

[114] Razumilava N.Cholangiocarcinoma..Lancet2014;383:2168-79

[115] Blechacz B.Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment..Hepatology2008;48:308-21 PMCID:PMC2547491

[116] Olaru AV,Yamanaka S,An F,Alexandrescu S,Pawlik TM,Georgiades C,Gores GJ,Almeida MI,Mezey E.MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint..Hepatology2011;54:2089-98 PMCID:PMC3212606

[117] Li L,Ishida M,Umegaki S,Georgiades C,Khashab M,Li Z,Lennon AM,Geschwind JF,Hong K,Canto M,Sharaiha R,Thuluvath P,Shin EJ,Kumbhari V,Zhou L,Meltzer SJ,Selaru FM.Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis..Hepatology2014;60:896-907 PMCID:PMC4121391

[118] Piontek K.MicroRNAs in the biology and diagnosis of cholangiocarcinoma..Semin Liver Dis2015;35:55-62

[119] Meng F,Lang M,Maheshwari S,Jiang J,Patel T.Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines..Gastroenterology2006;130:2113-29

[120] Kawahigashi Y,Mizuguchi Y,Yokomuro S,Ishibashi O,Tajiri T.MicroRNA profiling of human intrahepatic cholangiocarcinoma cell lines reveals biliary epithelial cell-specific microRNAs..J Nippon Med Sch2009;76:188-97

[121] Chen X,Liu X,Sun X.The real-time dynamic monitoring of microRNA function in cholangiocarcinoma..PLoS One2014;9:e99431

[122] Karakatsanis A,Gazouli M,Polymeneas G.Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance..Mol Carcinog2013;52:297-303

[123] McNally ME,Wojcik SE,Henry JC,Schmittgen T.Concomitant dysregulation of microRNAs miR-151-3p and miR-126 correlates with improved survival in resected cholangiocarcinoma..HPB (Oxford).2013;15:260-4

[124] Okamoto K,Murawaki Y.miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells..PLoS One2013;8:e77623

[125] Kaur S,Momi N,Batra SK.Mucins in pancreatic cancer and its microenvironment..Nat Rev Gastroenterol Hepatol2013;10:607-20

[126] Camacho D,Duerr GD,Sweeney JF.Value of laparoscopy in the staging of pancreatic cancer..JOP2005;6:552-61

[127] Burris HA,Moore MJ,Green MR,Modiano MR,Portenoy RK,Tarassoff P,Dorr FA,Von Hoff DD.Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial..J Clin Oncol1997;15:2403-13

[128] Cardenes HR,Johnson CS,Helft P,Vinson J,Stephens AW,Loehrer PJSr.A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group study..Am J Clin Oncol2011;34:460-5

[129] Tang YT,Yang XD,Cao H,Zhang SY.Role of non-coding RNAs in pancreatic cancer: the bane of the microworld..World J Gastroenterol2014;20:9405-17

[130] Sun T,Du Y.Aberrant MicroRNAs in Pancreatic Cancer: Researches and Clinical Implications..Gastroenterol Res Pract2014;2014:386561

[131] Halkova T,Minarik M.MicroRNAs in Pancreatic Cancer: Involvement in Carcinogenesis and Potential Use for Diagnosis and Prognosis..Gastroenterol Res Pract2015;2015:892903 PMCID:PMC4417562

[132] Kong X,Wang G,Gong Y,Zhang Z,Jing Q,Li Z.Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis..Dig Dis Sci2011;56:602-9

[133] Wang J,Chang P,Li D,Frazier ML,Sen S.MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease..Cancer Prev Res (Phila)2009;2:807-13 PMCID:PMC5859193

[134] Li A,Kim H,Canto MI,Goggins M.Serum miR-1290 as a marker of pancreatic cancer--response..Clin Cancer Res2013;19:5252-3 PMCID:PMC3783000

[135] Kawaguchi T,Ichikawa D,Tsujiura M,Takeshita H,Arita T,Shiozaki A,Okamoto K,Taniguchi H.Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer..Br J Cancer2013;108:361-9 PMCID:PMC3566805

[136] Caponi S,Frampton AE,Santarpia L,Jiao LR,Falcone A,Meijer GA,Vasile E,Boggi U.The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms..Ann Oncol2013;24:734-41

[137] Lubezky N,Ben-Haim M,Marmor S,Oron-Karni V,Klausner JM.MicroRNA expression signatures in intraductal papillary mucinous neoplasm of the pancreas..Surgery2013;153:663-72

[138] Farrell JJ,Wu N,Wong J,Tran LM,Li X,Wu H.Endoscopically acquired pancreatic cyst fluid microRNA 21 and 221 are associated with invasive cancer..Am J Gastroenterol2013;108:1352-9

[139] Dillhoff M,Frankel W,Bloomston M.MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival..J Gastrointest Surg2008;12:2171-6 PMCID:PMC4055565

[140] Jamieson NB,Morton JP,Dickson EJ,Sansom OJ,McKay CJ.MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma..Clin Cancer Res2012;18:534-45

[141] Frampton AE,Colombo T,Krell J,Pellegrino L,Funel N,De Giorgio A,Fulci V,Ahmad R,Coombes RC,Knosel T,Jiao LR.MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progression..Gastroenterology2014;146:268-77.e18

[142] Yu J,Mizumoto K,Kayashima T,Nakata K.MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation..Mol Cancer2010;9:169 PMCID:PMC2909980

[143] Radhakrishnan P,Grandgenett PM,Batra SK.MicroRNA-200c modulates the expression of MUC4 and MUC16 by directly targeting their coding sequences in human pancreatic cancer..PLoS One2013;8:e73356

[144] Greither T,Udelnow A,Wurl P.Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival..Int J Cancer2010;126:73-80

[145] Bloomston M,Petrocca F,Alder H,Liu CG,Taccioli C.MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis..JAMA2007;297:1901-8

[146] Lee C,Jiang Y,Yang F,Jin C.Elevated expression of tumor miR-222 in pancreatic cancer is associated with Ki67 and poor prognosis..Med Oncol2013;30:700

[147] Zhu Z,Du J,Jiao H.Expression of microRNA-218 in human pancreatic ductal adenocarcinoma and its correlation with tumor progression and patient survival..J Surg Oncol2014;109:89-94

[148] Giovannetti E,Peters GJ,Erozenci LA,Leon LG,Groen A,Danesi R,Verheul HM.MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity..Cancer Res2010;70:4528-38

[149] Hwang JH,Giovannetti E,Leon LG,Funel N,Kim MA,Kim SW,Peters GJ.Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer..PLoS One2010;5:e10630

[150] Sicard F,Lulka H,Cordelier P.Targeting miR-21 for the therapy of pancreatic cancer..Mol Ther2013;21:986-94 PMCID:PMC3666633

[151] Ji Q,Zhang M,Yang M,Xiang D,Bommer GT,Fearon ER,Xu L.MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells..PLoS One2009;4:e6816

[152] Weiss FU,Woltering JM,Aghdassi A,Heidecke CD,Bagowski CP.Retinoic acid receptor antagonists inhibit miR-10a expression and block metastatic behavior of pancreatic cancer..Gastroenterology2009;137:2136-45.e1-7

[153] Li Y,2nd,Kong D,Philip PA.miR-146a suppresses invasion of pancreatic cancer cells..Cancer Res2010;70:1486-95 PMCID:PMC2978025